Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 12, 2017, Pages 3374-3381

  Fransen, Fiona ^a,b   Hermans, Kelly ^a   Melchers, Maria J B ^a,b   Lagarde, Claudia C M ^a,b   Meletiadis, Joseph ^b,c   Mouton, Johan W ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CITROBACTER FREUNDII; COLONY FORMING UNIT; COMPARATIVE STUDY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; KLEBSIELLA PNEUMONIAE; LIMIT OF DETECTION; MAXIMUM DRUG EFFECT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; QUALITY CONTROL; DRUG EFFECT; ENTEROBACTERIACEAE; ENZYMOLOGY; GENETIC SELECTION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; SECRETION (PROCESS);

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; FOSFOMYCIN; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; SELECTION, GENETIC;

EID: 85041546984     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx328     Document Type: Article

References (29)

1. Hendlin D, Stapley EO, JacksonMet al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 1969; 166: 122-3
2. Falagas ME, Kastoris AC, Kapaskelis AM et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10: 43-50
3. Walsh CC, McIntosh MP, Peleg AY et al. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 2015; 70: 3042-50
4. Mazzei T, Cassetta MI, Fallani S et al. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents 2006; 28: S35-41
5. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine-a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997; 53: 637-56
6. Pullukcu H, Tasbakan M, Sipahi OR et al. Fosfomycin in the treatment of extended spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29: 62-5
7. Parker S, Lipman J, Koulenti D et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents 2013; 42: 289-93
8. Falagas ME, Giannopoulou KP, Kokolakis GN et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008; 46: 1069-77
9. Michalopoulos A, Virtzili S, Rafailidis P et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16: 184-6
10. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011; 15: e732-9
11. Roussos N, Karageorgopoulos DE, Samonis G et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009; 34: 506-15
12. Grif K, Dierich MP, Pfaller K et al. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 2001; 48: 209-17
13. MacLeod DL, Barker LM, Sutherland JL et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009; 64: 829-36
14. Oliva A, Tafin UF, Maiolo EM et al. Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model. Antimicrob Agents Chemother 2014; 58: 1284-93
15. Pfausler B, Spiss H, Dittrich P et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomyassociated ventriculitis.JAntimicrobChemother 2004; 53: 848-52
16. Ribes S, Taberner F, Domenech A et al. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae.JAntimicrobChemother 2006; 57: 931-6
17. Karageorgopoulos DE, Wang R, Yu XH et al. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gramnegative pathogens. J Antimicrob Chemother 67: 255-68
18. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_ tables/v_7.0_Breakpoint_Tables.pdf
19. Mouton J, Voss A, Arends J et al. Prevalence of ESBL in the Netherlands: theONE study. Int J Antimicrob Agents 2007; 29: S91-2
20. International Organization for Standardization. Clinical Laboratory Testing and In Vitro Diagnostic Test Systems: Susceptibility Testing of Infectious Agents and Evaluation of Performance of Antimicrobial Susceptibility Test Devices Part 1: Reference Method for Testing the In Vitro Activity of Antimicrobial Agents against Rapidly Growing Aerobic Bacteria Involved in Infectious Diseases ISO 20776-1. 2006. https://www.iso.org/obp/ ui/#iso:std:iso:20776:-1:ed-1:v1:en
21. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/ pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. JAntimicrobChemother 2005; 55: 601-7
22. Mouton JW, Vinks AA. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 2005; 44: 201-10
23. LepakAJ, ZhaoM, VanScoyBet al. In vivo pharmacokinetics and pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2017; 61: 476-17
24. Fransen F, Melchers MJ, Meletiadis J et al. Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections. J Antimicrob Chemother 2016; 71: 2883-9
25. Docobo-Pérez F, Drusano GL, Johnson A et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother 2015; 59: 5602-10
26. AlburMS, NoelA, Bowker K et al. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. Int J Antimicrob Agents 2015; 46: 560-7
27. Corvec S, Furustrand Tafin U, Betrisey B et al. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamaseproducing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother 2013; 57: 1421-7
28. EUCAST. Antimicrobial Wild Type Distributions of Microorganisms (Fosfomycin). https://mic.eucast.org/Eucast2
29. Ballestero-TéllezM, Docobo-Pérez F, Portillo-Calderón I et al. Molecular insights into fosfomycin resistance in Escherichia coli. J Antimicrob Chemother 2017; 72: 1303-9